Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing Requirements

2025-06-17T09:38:38+02:00June 17, 2025|Investor Information, Press Releases, Psychedelic News|

Psyence Biomedical Ltd. announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows a successful compliance hearing held on May 29, 2025.